{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T13:06:05Z","timestamp":1789909565379,"version":"4.0.1"},"reference-count":249,"publisher":"National Institute for Health and Care Research","issue":"24","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.nationalarchives.gov.uk\/doc\/non-commercial-government-licence\/non-commercial-government-licence.htm"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment programme","doi-asserted-by":"publisher","award":["12\/44\/01"],"award-info":[{"award-number":["12\/44\/01"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Health Technol Assess"],"abstract":"Background<\/jats:title>Typically occurring on the external genitalia, anogenital warts (AGWs) are benign epithelial skin lesions caused by human papillomavirus infection. AGWs are usually painless but can be unsightly and physically uncomfortable, and affected people might experience psychological distress. The evidence base on the clinical effectiveness and cost-effectiveness of treatments for AGWs is limited.<\/jats:p><\/jats:sec>Objectives<\/jats:title>To systematically review the evidence on the clinical effectiveness of medical and surgical treatments for AGWs and to develop an economic model to estimate the cost-effectiveness of the treatments.<\/jats:p><\/jats:sec>Data sources<\/jats:title>Electronic databases (MEDLINE, MEDLINE In-Process & Other Non-Indexed Citations, EMBASE, The Cochrane Library databases and Web of Science) were searched from inception (or January 2000 for Web of Science) to September 2014. Bibliographies of relevant systematic reviews were hand-searched to identify potentially relevant studies. The World Health Organization International Clinical Trials Registry Platform and ClinicalTrials.gov were searched for ongoing and planned studies.<\/jats:p><\/jats:sec>Review methods<\/jats:title>A systematic review of the clinical effectiveness literature was carried out according to standard methods and a mixed-treatment comparison (MTC) undertaken. The model implemented for each outcome was that with the lowest deviance information criterion. A de novo economic model was developed to assess cost-effectiveness from the perspective of the UK NHS. The model structure was informed through a systematic review of the economic literature and in consultation with clinical experts. Effectiveness data were obtained from the MTC. Costs were obtained from the literature and standard UK sources.<\/jats:p><\/jats:sec>Results<\/jats:title>Of 4232 titles and abstracts screened for inclusion in the review of clinical effectiveness, 60 randomised controlled trials (RCTs) evaluating 19 interventions were included. Analysis by MTC indicated that ablative techniques were typically more effective than topical interventions at completely clearing AGWs at the end of treatment. Podophyllotoxin 0.5% solution (Condyline\u00ae<\/jats:sup>, Takeda Pharmaceutical Company Ltd; Warticon\u00ae<\/jats:sup>solution, Stiefel Laboratories Ltd) was found to be the most effective topical treatment evaluated. Networks for other outcomes included fewer treatments, which restrict conclusions on the comparative effectiveness of interventions. In total, 84 treatment strategies were assessed using the economic model. Podophyllotoxin 0.5% solution first line followed by carbon dioxide (CO2<\/jats:sub>) laser therapy second line if AGWs did not clear was most likely to be considered a cost-effective use of resources at a willingness to pay of \u00a320,000\u201330,000 per additional quality-adjusted life-year gained. The result was robust to most sensitivity analyses conducted.<\/jats:p><\/jats:sec>Limitations<\/jats:title>Limited reporting in identified studies of baseline characteristics for the enrolled population generates uncertainty around the comparability of the study populations and therefore the generalisability of the results to clinical practice. Subgroup analyses were planned based on type, number and size of AGWs, all of which are factors thought to influence treatment effect. Lack of data on clinical effectiveness based on these characteristics precluded analysis of the differential effects of treatments in the subgroups of interest. Despite identification of 60 studies, most comparisons in the MTC are informed by only one RCT. Additionally, lack of head-to-head RCTs comparing key treatments, together with minimal reporting of results in some studies, precluded comprehensive analysis of all treatments for AGWs.<\/jats:p><\/jats:sec>Conclusions<\/jats:title>The results generated by the MTC are in agreement with consensus opinion that ablative techniques are clinically more effective at completely clearing AGWs after treatment. However, the evidence base informing the MTC is limited. A head-to-head RCT that evaluates the comparative effectiveness of interventions used in clinical practice would help to discern the potential advantages and disadvantages of the individual treatments. The results of the economic analysis suggest that podophyllotoxin 0.5% solution is likely to represent a cost-effective first-line treatment option. More expensive effective treatments, such as CO2<\/jats:sub>laser therapy or surgery, may represent cost-effective second-line treatment options. No treatment and podophyllin are unlikely to be considered cost-effective treatment options. There is uncertainty around the cost-effectiveness of treatment with imiquimod, trichloroacetic acid and cryotherapy.<\/jats:p><\/jats:sec>Study registration<\/jats:title>This study is registered as PROSPERO CRD42013005457.<\/jats:p><\/jats:sec>Funding<\/jats:title>The National Institute for Health Research Health Technology Assessment programme.<\/jats:p><\/jats:sec>","DOI":"10.3310\/hta20240","type":"journal-article","created":{"date-parts":[[2016,4,5]],"date-time":"2016-04-05T08:50:48Z","timestamp":1459846248000},"page":"1-486","update-policy":"https:\/\/doi.org\/10.3310\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":55,"title":["Clinical effectiveness and cost-effectiveness of interventions for the treatment of anogenital warts: systematic review and economic evaluation"],"prefix":"10.3310","volume":"20","author":[{"given":"Elizabeth","family":"Thurgar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Barton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotta","family":"Karner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven J","family":"Edwards","sequence":"additional","affiliation":[{"name":"BMJ Technology Assessment Group, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6221","published-online":{"date-parts":[[2016,3]]},"reference":[{"key":"key20160405092302285_ref1-bib1","volume-title":"Genital Warts","author":"NHS Choices","year":"2012"},{"key":"key20160405092302285_ref1-bib2","volume-title":"Total Number of STI Diagnoses and other Episodes of Care Seen at Genitourinary Medicine Clinics, UK & England","author":"Health Protection Agency","year":"2014"},{"key":"key20160405092302285_ref1-bib3","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1136\/sti.2010.048421","article-title":"Genital warts and cost of care in England","volume":"87","author":"Desai","year":"2011","journal-title":"Sex Transm Infect"},{"key":"key20160405092302285_ref1-bib4","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.1016\/j.jcv.2004.12.008","article-title":"The epidemiology of human papillomavirus infections","volume":"32","author":"Baseman","year":"2005","journal-title":"J Clin Virol"},{"key":"key20160405092302285_ref1-bib5","volume-title":"United Kingdom National Guideline on the Management of Anogenital Warts","author":"British Association for Sexual Health and HIV","year":"2007"},{"key":"key20160405092302285_ref1-bib6","doi-asserted-by":"publisher","first-page":"e263","DOI":"10.1111\/j.1468-3083.2012.04493.x","article-title":"2012 European guideline for the management of anogenital warts","volume":"27","author":"Lacey","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"key20160405092302285_ref1-bib7","volume-title":"UK National Guidelines on the Management of Anogenital Warts 2014. Draft Guidelines","author":"British Association for Sexual Health and HIV","year":"2014"},{"key":"key20160405092302285_ref1-bib8","doi-asserted-by":"publisher","first-page":"326369","DOI":"10.1155\/2010\/326369","article-title":"Evidence for vertical transmission of HPV from mothers to infants","volume":"2010","author":"Smith","year":"2010","journal-title":"Infect Dis Obstet Gynecol"},{"key":"key20160405092302285_ref1-bib9","doi-asserted-by":"publisher","first-page":"CD006562","DOI":"10.1002\/14651858.cd006562.pub2","article-title":"5-FU for genital warts in non-immunocompromised individuals","volume":"4","author":"Batista","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"key20160405092302285_ref1-bib10","volume-title":"Sexually Transmitted Diseases","author":"Holmes","year":"2008","edition":"4th edn."},{"key":"key20160405092302285_ref1-bib11","volume-title":"Warts (Genital)","author":"Buck","year":"2015"},{"key":"key20160405092302285_ref1-bib12","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1136\/sti.76.3.162","article-title":"European course on HPV associated pathology: guidelines for primary care physicians for the diagnosis and management of anogenital warts","volume":"76","author":"von Krogh","year":"2000","journal-title":"Sex Transm Infect"},{"key":"key20160405092302285_ref1-bib13","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/1471-2334-13-39","article-title":"Systematic review of the incidence and prevalence of genital warts","volume":"13","author":"Patell","year":"2013","journal-title":"BMC Infect Dis"},{"key":"key20160405092302285_ref1-bib14","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1086\/421279","article-title":"Prevalence and determinants of genital infection with papillomavirus, in female and male university students in Busan, South Korea","volume":"190","author":"Shin","year":"2004","journal-title":"J Infect Dis"},{"key":"key20160405092302285_ref1-bib15","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1093\/infdis\/174.4.679","article-title":"Sexual behavior and partner characteristics are the predominant risk factors for genital human papillomavirus infection in young women","volume":"174","author":"Burk","year":"1996","journal-title":"J Infect Dis"},{"key":"key20160405092302285_ref1-bib16","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1099\/0022-1317-70-8-2227","article-title":"Oestrogen stimulates differential transcription of human papillomavirus type 16 in SiHa cervical carcinoma cells","volume":"70","author":"Mitrani-Rosenbaum","year":"1989","journal-title":"J Gen Virol"},{"key":"key20160405092302285_ref1-bib17","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1056\/NEJMoa011688","article-title":"Male circumcision, penile human papillomavirus infection, and cervical cancer in female partners","volume":"346","author":"Castellsagu\u00e9","year":"2002","journal-title":"N Engl J Med"},{"key":"key20160405092302285_ref1-bib18","first-page":"2335","article-title":"Management of genital warts","volume":"70","author":"Kodner","year":"2004","journal-title":"Am Fam Physician"},{"key":"key20160405092302285_ref1-bib19","doi-asserted-by":"publisher","first-page":"S210","DOI":"10.1086\/342109","article-title":"External genital warts: diagnosis, treatment, and prevention","volume":"35","author":"Wiley","year":"2002","journal-title":"Clin Infect Dis"},{"key":"key20160405092302285_ref1-bib20","volume-title":"Sexually Transmitted Diseases Treatment Guidelines, 2006","author":"Centers for Disease Control and Prevention","year":"2006"},{"key":"key20160405092302285_ref1-bib21","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1136\/bmj.300.6722.459","article-title":"Genital warts: need to screen for coinfection","volume":"300","author":"Carne","year":"1990","journal-title":"BMJ"},{"key":"key20160405092302285_ref1-bib22","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1258\/095646206777323328","article-title":"Incidence of concurrent sexually transmitted infections in patients with genital warts","volume":"17","author":"Griffiths","year":"2006","journal-title":"Int J STD AIDS"},{"key":"key20160405092302285_ref1-bib23","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1258\/0956462961918086","article-title":"Characterizing patients with multiple sexually acquired infections: a multivariate analysis","volume":"7","author":"Pakianathan","year":"1996","journal-title":"Int J STD AIDS"},{"key":"key20160405092302285_ref1-bib24","volume-title":"Warts \u2013 Anogenital. Clinical Knowledge Summaries","author":"National Institute for Health and Care Excellence","year":"2012"},{"key":"key20160405092302285_ref1-bib25","volume-title":"IARC Monograph on the Evaluation of Carcinogenic Risks to Humans. Volume 90: Human Papillomaviruses","author":"World Health Organization International Agency for Research on Cancer","year":"2007"},{"key":"key20160405092302285_ref1-bib26","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1056\/NEJMoa021641","article-title":"Epidemiologic classification of human papillomavirus types associated with cervical cancer","volume":"348","author":"Mu\u00f1oz","year":"2003","journal-title":"N Engl J Med"},{"key":"key20160405092302285_ref1-bib27","volume-title":"Health Protection Report. Trends in Genital Herpes and Genital Warts Infections, United Kingdom: 2000 to 2009","author":"Health Protection Agency","year":"2011"},{"key":"key20160405092302285_ref1-bib28","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/S0002-9343(97)00182-4","article-title":"Counseling patients with genital warts","volume":"102","author":"Reitano","year":"1997","journal-title":"Am J Med"},{"key":"key20160405092302285_ref1-bib29","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1258\/0956462961917618","article-title":"The psychosocial impact of human papillomavirus infection: implications for health care providers","volume":"7","author":"Clarke","year":"1996","journal-title":"Int J STD AIDS"},{"key":"key20160405092302285_ref1-bib30","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1258\/ijsa.2008.008412","article-title":"\u2018Shame on you\u2019 \u2013 the psychosocial impact of genital warts","volume":"20","author":"Jeynes","year":"2009","journal-title":"Int J STD AIDS"},{"key":"key20160405092302285_ref1-bib31","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1097\/00007435-199301000-00003","article-title":"Physical and psychological effects of anogenital warts on female patients","volume":"20","author":"Persson","year":"1993","journal-title":"Sex Transm Dis"},{"key":"key20160405092302285_ref1-bib32","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1136\/sti.2007.029512","article-title":"Estimation of the impact of genital warts on health-related quality of life","volume":"84","author":"Woodhall","year":"2008","journal-title":"Sex Transm Infect"},{"key":"key20160405092302285_ref1-bib33","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1258\/095646205774357334","article-title":"The role of illness perceptions: psychological distress and treatment-seeking delay in patients with genital warts","volume":"16","author":"Ireland","year":"2005","journal-title":"Int J STD AIDS"},{"key":"key20160405092302285_ref1-bib34","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1136\/sti.2006.023333","article-title":"The association between knowledge of HPV and feelings of stigma, shame and anxiety","volume":"83","author":"Waller","year":"2007","journal-title":"Sex Transm Infect"},{"key":"key20160405092302285_ref1-bib35","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1258\/0956462981921143","article-title":"An international survey of patients with genital warts: perceptions regarding treatment and impact on lifestyle","volume":"9","author":"Maw","year":"1998","journal-title":"Int J STD AIDS"},{"key":"key20160405092302285_ref1-bib36","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/1477-7525-3-24","article-title":"Combination of qualitative and quantitative methods for developing a new health related quality of life measure for patients with anogenital warts","volume":"3","author":"Badia","year":"2005","journal-title":"Health Qual Life Outcomes"},{"key":"key20160405092302285_ref1-bib37","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/1471-2458-10-113","article-title":"The quality of life of patients with genital warts: a qualitative study","volume":"10","author":"Mortensen","year":"2010","journal-title":"BMC Public Health"},{"key":"key20160405092302285_ref1-bib38","first-page":"A4140","article-title":"Long-term quality of life effects of genital warts \u2013 a follow-study","volume":"57","author":"Mortensen","year":"2010","journal-title":"Dan Med Bull"},{"key":"key20160405092302285_ref1-bib39","volume-title":"British National Formulary","author":"Joint Formulary Committee","year":"2014","edition":"68th edn."},{"key":"key20160405092302285_ref1-bib40","volume-title":"Cervarix","author":"European Medicines Agency","year":"2014"},{"key":"key20160405092302285_ref1-bib41","volume-title":"Gardasil","author":"European Medicines Agency","year":"2014"},{"key":"key20160405092302285_ref1-bib42","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1056\/NEJMoa061741","volume":"356","author":"Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions","year":"2007","journal-title":"N Engl J Med"},{"key":"key20160405092302285_ref1-bib43","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1016\/S0140-6736(07)60946-5","article-title":"Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a Phase III double-blind, randomised controlled trial","volume":"369","author":"Paavonen","year":"2007","journal-title":"Lancet"},{"key":"key20160405092302285_ref1-bib44","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1086\/597307","article-title":"The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16\u201326 years","volume":"199","author":"Brown","year":"2009","journal-title":"J Infect Dis"},{"key":"key20160405092302285_ref1-bib45","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1086\/597309","article-title":"The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16\u201326 years","volume":"199","author":"Wheeler","year":"2009","journal-title":"J Infect Dis"},{"key":"key20160405092302285_ref1-bib46","volume-title":"Introduction of Human Papillomavirus Vaccine into the National Immunisation Programme: Announcement of Vaccine to be Used","author":"Department of Health","year":"2008"},{"key":"key20160405092302285_ref1-bib47","doi-asserted-by":"publisher","first-page":"a769","DOI":"10.1136\/bmj.a769","article-title":"Economic evaluation of human papillomavirus vaccination in the United Kingdom","volume":"337","author":"Jit","year":"2008","journal-title":"BMJ"},{"key":"key20160405092302285_ref1-bib48","volume-title":"Annual HPV Vaccine Coverage in England in 2009\/2010","author":"Department of Health","year":"2010"},{"key":"key20160405092302285_ref1-bib49","volume-title":"HPV Vaccine","author":"NHS Choices","year":"2014"},{"key":"key20160405092302285_ref1-bib50","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1136\/sti.2009.037788","article-title":"Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women","volume":"85","author":"Fairley","year":"2009","journal-title":"Sex Transm Infect"},{"key":"key20160405092302285_ref1-bib51","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1258\/ijsa.2011.011218","article-title":"The cost of managing genital warts in the UK","volume":"23","author":"Lanitis","year":"2012","journal-title":"Int J STD AIDS"},{"key":"key20160405092302285_ref1-bib52","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1093\/jac\/48.6.751","article-title":"Imiquimod and resiquimod as novel immunomodulators","volume":"48","author":"Dockrell","year":"2001","journal-title":"J Antimicrob Chemother"},{"key":"key20160405092302285_ref1-bib53","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1006\/cyto.1997.0239","article-title":"Induction of cytokines in cynomolgus monkeys by the immune response modifiers, imiquimod, S-27609 and S-28463","volume":"9","author":"Wagner","year":"1997","journal-title":"Cytokine"},{"key":"key20160405092302285_ref1-bib54","doi-asserted-by":"publisher","first-page":"9749","DOI":"10.1074\/jbc.273.16.9749","article-title":"Promoter structures and differential responses to viral and nonviral inducers of chicken type I interferon genes","volume":"273","author":"Sick","year":"1998","journal-title":"J Biol Chem"},{"key":"key20160405092302285_ref1-bib55","volume-title":"Aldara","author":"European Medicines Agency","year":"2014"},{"key":"key20160405092302285_ref1-bib56","volume-title":"Aldara: Clinical Executive Summary","author":"US Food and Drug Administration","year":"2007"},{"key":"key20160405092302285_ref1-bib57","volume-title":"Zyclara: Clinical Review","author":"US Food and Drug Administration","year":"2010"},{"key":"key20160405092302285_ref1-bib58","volume-title":"Aldara 5% Cream","author":"Electronic Medicines Compendium","year":"2014"},{"key":"key20160405092302285_ref1-bib59","doi-asserted-by":"publisher","first-page":"209","DOI":"10.2165\/00002018-200629030-00005","article-title":"Camptothecin and podophyllotoxin derivatives: inhibitors of topoisomerase I and II \u2013 mechanisms of action, pharmacokinetics and toxicity profile","volume":"29","author":"Hartmann","year":"2006","journal-title":"Drug Saf"},{"key":"key20160405092302285_ref1-bib60","doi-asserted-by":"publisher","first-page":"123","DOI":"10.3109\/09546639009086712","article-title":"Clinical efficacy of Condyline (0.5% podophyllotoxin solution and cream) versus podophyllin in the treatment of external condylomata acuminata","volume":"1","author":"Mazurkiewicz","year":"1990","journal-title":"J Dermatol Treat"},{"key":"key20160405092302285_ref1-bib61","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/0002-9343(90)90424-C","article-title":"Double-blind randomized clinical trial of self-administered podofilox solution versus vehicle in the treatment of genital warts","volume":"88","author":"Kirby","year":"1990","journal-title":"Am J Med"},{"key":"key20160405092302285_ref1-bib62","first-page":"735","article-title":"A double-blind, randomized trial of 0.5% podofilox and placebo for the treatment of genital warts in women","volume":"77","author":"Greenberg","year":"1991","journal-title":"Obstet Gynecol"},{"key":"key20160405092302285_ref1-bib63","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1177\/095646249300400403","article-title":"An open, comparative, study of the efficacy of 0.5% podophyllotoxin lotion and 25% podophyllotoxin solution in the treatment of condylomata acuminata in males and females","volume":"4","author":"Kinghorn","year":"1993","journal-title":"Int J STD AIDS"},{"key":"key20160405092302285_ref1-bib64","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1136\/sti.79.4.270","article-title":"Randomised controlled trial and economic evaluation of podophyllotoxin solution, podophyllotoxin cream, and podophyllin in the treatment of genital warts","volume":"79","author":"Lacey","year":"2003","journal-title":"Sex Transm Infect"},{"key":"key20160405092302285_ref1-bib65","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1258\/0956462961918400","article-title":"Topical treatment of venereal warts: a comparative open study of podophyllotoxin cream versus solution","volume":"7","author":"Claesson","year":"1996","journal-title":"Int J STD AIDS"},{"key":"key20160405092302285_ref1-bib66","first-page":"17","article-title":"Comparing treatment response and complications between podophyllin 0.5%\/0.25% in ethanol vs. podophyllin 25% in tincture benzoin for penile warts","volume":"39","author":"Goh","year":"1998","journal-title":"Singapore Med J"},{"key":"key20160405092302285_ref1-bib67","first-page":"56","article-title":"Self-treatment of primary anogenital warts in men with podophyllin 0.5% in ethanol compared with podophyllotoxin (Condyline): a randomised double blind comparative study","volume":"161","author":"Handley","year":"1992","journal-title":"Ir J Med Sci"},{"key":"key20160405092302285_ref1-bib68","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1001\/archderm.134.1.33","article-title":"Safety and efficacy of 0.5% podofilox gel in the treatment of anogenital warts","volume":"134","author":"Tyring","year":"1998","journal-title":"Arch Dermatol"},{"key":"key20160405092302285_ref1-bib69","volume-title":"Condyline","author":"Electronic Medicines Compendium","year":"2014"},{"key":"key20160405092302285_ref1-bib70","volume-title":"Warticon Solution","author":"Electronic Medicines Compendium","year":"2014"},{"key":"key20160405092302285_ref1-bib71","volume-title":"Warticon Cream","author":"Electronic Medicines Compendium","year":"2014"},{"key":"key20160405092302285_ref1-bib72","volume-title":"Cidofovir: an Overview","author":"Rodriguez","year":"2014"},{"key":"key20160405092302285_ref1-bib73","volume-title":"Diagnosis and Management of Genital Warts in HIV Disease","author":"Orlando","year":"2000"},{"key":"key20160405092302285_ref1-bib74","volume-title":"Vistide","author":"European Medicines Agency","year":"2014"},{"key":"key20160405092302285_ref1-bib75","first-page":"30","article-title":"Food and Drug Administration","volume":"2","author":"FDA approves cidofovir for treatment of CMV retinitis","year":"1996","journal-title":"J Int Assoc Physicians AIDS Care"},{"key":"key20160405092302285_ref1-bib76","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1128\/CMR.16.4.569-596.2003","article-title":"Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections","volume":"16","author":"De Clercq","year":"2003","journal-title":"Clin Microbiol Rev"},{"key":"key20160405092302285_ref1-bib77","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1136\/sti.71.2.92","article-title":"Quercetin and kaempherol: an argument against the use of podophyllin?","volume":"71","author":"Petersen","year":"1995","journal-title":"Genitourin Med"},{"key":"key20160405092302285_ref1-bib78","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1080\/00365590050509959","article-title":"The management and prevention of premalignant penile lesions","volume":"205","author":"von Krogh","year":"2000","journal-title":"Scand J Urol Nephrol Suppl"},{"key":"key20160405092302285_ref1-bib79","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1126\/science.327550","article-title":"Mutagenic activity of quercetin and related compounds","volume":"197","author":"Bjeldanes","year":"1977","journal-title":"Science"},{"key":"key20160405092302285_ref1-bib80","first-page":"3468","article-title":"Quercetin, a rat intestinal and bladder carcinogen present in bracken fern (Pteridium aquilinum)","volume":"40","author":"Pamukcu","year":"1980","journal-title":"Cancer Res"},{"key":"key20160405092302285_ref1-bib81","volume-title":"Podophyllum Resin: Summary of Product Characteristics","author":"Medicines and Healthcare products Regulatory Agency","year":"2005"},{"key":"key20160405092302285_ref1-bib82","first-page":"25","article-title":"Genital warts: a comprehensive review","volume":"5","author":"Yanofsky","year":"2012","journal-title":"J Clin Aesthet Dermatol"},{"key":"key20160405092302285_ref1-bib83","doi-asserted-by":"publisher","first-page":"141","DOI":"10.4103\/2249-4863.117403","article-title":"Hyfrecation for recalcitrant nongenital warts","volume":"2","author":"Leung","year":"2013","journal-title":"J Family Med Prim Care"},{"key":"key20160405092302285_ref1-bib84","volume-title":"CRD\u2019s Guidance for Undertaking Reviews in Health Care","author":"Centre for Reviews and Dissemination","year":"2011"},{"key":"key20160405092302285_ref1-bib85","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2009"},{"key":"key20160405092302285_ref1-bib86","volume-title":"Clinical and Cost Effectiveness of Interventions for the Treatment of Anogenital Warts: Systematic Review and Economic Evaluation","author":"Edwards","year":"2014"},{"key":"key20160405092302285_ref1-bib87","volume-title":"The InterTASC Information Specialists\u2019 Sub-Group Search Filter Resource","author":"Information Specialists\u2019 Sub-Group","year":"2013"},{"key":"key20160405092302285_ref1-bib88","volume-title":"Search Filters","author":"Scottish Intercollegiate Guidelines Network","year":"2013"},{"key":"key20160405092302285_ref1-bib89","volume-title":"Study Design Search Filters","author":"Clinical Evidence","year":"2013"},{"key":"key20160405092302285_ref1-bib90","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"key20160405092302285_ref1-bib91","volume-title":"NICE DSU Technical Support Document 2: A Generalised Linear Modelling Framework for Pairwise and Network Meta-Analysis of Randomised Controlled Trials","author":"Dias","year":"2011"},{"key":"key20160405092302285_ref1-bib92","volume-title":"NICE DSU Technical Support Document 1: Introduction to Evidence Synthesis for Decision Making","author":"Dias","year":"2013"},{"key":"key20160405092302285_ref1-bib93","first-page":"972","volume":"25","author":"Imiquimod \u2013 Aldara\u00ae \u2013 treatment of genital warts \u2013 oncolytic \u2013 immunomodulator","year":"2000","journal-title":"Drugs Future"},{"key":"key20160405092302285_ref1-bib94","first-page":"256","article-title":"The curative effect observation of home-made podophyllotoxin in external use for condyloma acuminatum","volume":"9","author":"Biao","year":"1995","journal-title":"Chin J Dermatovenereol"},{"key":"key20160405092302285_ref1-bib95","first-page":"111","article-title":"Molecular detection of human papillomavirus in women with cervical condylomas treated with trichloroacetic acid","volume":"73","author":"Cort\u00e9s Guti\u00e9rrez","year":"2005","journal-title":"Ginecol Obstet Mex"},{"key":"key20160405092302285_ref1-bib96","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/S0213-9251(09)70750-6","article-title":"Trichloroacetic acid versus cryosurgery in the condyloma acuminata topical treatment","volume":"24","author":"Alfonso-Trujillo","year":"2009","journal-title":"Piel"},{"key":"key20160405092302285_ref1-bib97","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/S0213-9251(09)72017-9","article-title":"Condyloma acuminate: efficacy of podophyllin alone vs. podophyllin associated with levamisole","volume":"24","author":"Alfonso-Trujillo","year":"2009","journal-title":"Piel"},{"key":"key20160405092302285_ref1-bib98","first-page":"433","article-title":"Condyloma acuminata: comparative therapeutic efficacy of cryosurgery vs. cryosurgery associated with levamisole","volume":"258","author":"Alfonso-Trujillo","year":"2014","journal-title":"Piel"},{"key":"key20160405092302285_ref1-bib99","first-page":"225","article-title":"Observation of 6 methods of treating condyloma acuminatum (genital warts)","volume":"4","author":"Liu","year":"1998","journal-title":"J Chin AIDS\/STD Prev Cont"},{"key":"key20160405092302285_ref1-bib100","article-title":"Laser therapy of human papilloma virus associated genital warts","volume":"52","author":"Mueller","journal-title":"Lasers Surg Med"},{"key":"key20160405092302285_ref1-bib101","doi-asserted-by":"publisher","first-page":"84","DOI":"10.4103\/0253-7184.62763","article-title":"A study on the use of imiquimod for the treatment of genital molluscum contagiosum and genital warts in female patients","volume":"30","author":"Puri","year":"2009","journal-title":"Indian J Sex Transm Dis"},{"key":"key20160405092302285_ref1-bib102","first-page":"117","article-title":"The clinical observation of Podophyllinresin solution for condyloma acuminatum","volume":"9","author":"Qian","year":"1995","journal-title":"Chin J Dermatovenereol"},{"key":"key20160405092302285_ref1-bib103","first-page":"IC1612","article-title":"Imiquimod 5% versus podophyllotoxin 0.5% in cream for the treatment of genital warts. A placebo-controlled, double-blind, comparative study","author":"Syed","year":"2002","journal-title":"Ann Dermatol Venereol"},{"key":"key20160405092302285_ref1-bib104","first-page":"139","article-title":"The comparative study of 3 kinds therapy methods in treating condyloma acuminatum","volume":"14","author":"Wang","year":"2000","journal-title":"Chin J Dermatovenereol"},{"key":"key20160405092302285_ref1-bib105","first-page":"35","article-title":"The curative effect observation of 30 cases home made Podphyllotoxin for Condyloma acuminatum","volume":"9","author":"Wang","year":"1995","journal-title":"Chin J Dermatovenereol"},{"key":"key20160405092302285_ref1-bib106","first-page":"200","volume":"28","author":"Podophyllotoxin 0.5% tincture in the treatment of 32 cases of condyloma acuminatum","year":"1995","journal-title":"Chin J Dermatovenereol"},{"key":"key20160405092302285_ref1-bib107","first-page":"240","article-title":"Treatment of multiple condyloma acuminatum of the coronary sulcus with sleeve circumcision of prepuce and coronary sulcus skin (a report of 35 cases)","volume":"12","author":"Luo","year":"2006","journal-title":"Zhonghua Nan Ke Xue"},{"key":"key20160405092302285_ref1-bib108","first-page":"564","article-title":"Clinical study on treatment of condyloma acuminata with 0.5% podophyllotoxin film","volume":"36","author":"Wu","year":"2001","journal-title":"Chin Pharm J"},{"key":"key20160405092302285_ref1-bib109","first-page":"117","article-title":"The contrast of clinical efficacy of three ways for condyloma acuminatum","volume":"9","author":"Xiao","year":"1995","journal-title":"Chin J Dermatovenereol"},{"key":"key20160405092302285_ref1-bib110","first-page":"119","article-title":"Effect analysis of three therapies for condyloma acuminatum","volume":"12","author":"Yu","year":"1998","journal-title":"Chin J Dermatovenereol"},{"key":"key20160405092302285_ref1-bib111","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/1745-6215-10-46","article-title":"Randomized trials published in some Chinese journals: how many are randomized?","volume":"10","author":"Wu","year":"2009","journal-title":"Trials"},{"key":"key20160405092302285_ref1-bib112","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1111\/j.1346-8138.2004.tb00568.x","article-title":"Topical imiquimod 5% cream in external anogenital warts: a randomized, double-blind, placebo-controlled study","volume":"31","author":"Arican","year":"2004","journal-title":"J Dermatol"},{"key":"key20160405092302285_ref1-bib113","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.contraception.2010.04.129","article-title":"Imiquimod 2.5% and 3.75% applied daily for up to 8 weeks to treat external genital warts","volume":"82","author":"Baker","year":"2010","journal-title":"Contraception"},{"key":"key20160405092302285_ref1-bib114","first-page":"393","article-title":"Randomized clinical trial comparing systemic interferon with diathermocoagulation in primary multiple and widespread anogenital condyloma","volume":"74","author":"Benedetti Panici","year":"1989","journal-title":"Obstet Gynecol"},{"key":"key20160405092302285_ref1-bib115","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/S0140-6736(89)92282-4","article-title":"Patient-applied podofilox for treatment of genital warts","volume":"1","author":"Beutner","year":"1989","journal-title":"Lancet"},{"key":"key20160405092302285_ref1-bib116","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1128\/AAC.42.4.789","article-title":"Imiquimod, a patient-applied immune-response modifier for treatment of external genital warts","volume":"42","author":"Beutner","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"key20160405092302285_ref1-bib117","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/S0190-9622(98)70243-9","article-title":"Treatment of genital warts with an immune-response modifier (imiquimod)","volume":"38","author":"Beutner","year":"1998","journal-title":"J Am Acad Dermatol"},{"key":"key20160405092302285_ref1-bib118","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1001\/archderm.134.1.25","article-title":"Self-administered topical 5% imiquimod cream for external anogenital warts. HPV Study Group. Human PapillomaVirus","volume":"134","author":"Edwards","year":"1998","journal-title":"Arch Dermatol"},{"key":"key20160405092302285_ref1-bib119","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1097\/00002030-199912030-00011","article-title":"A randomized, controlled, safety study using imiquimod for the topical treatment of anogenital warts in HIV-infected patients. Imiquimod Study Group","volume":"13","author":"Gilson","year":"1999","journal-title":"AIDS"},{"key":"key20160405092302285_ref1-bib120","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1097\/00007435-200106000-00007","article-title":"Efficacy and tolerability of topical 1% cidofovir cream for the treatment of external anogenital warts in HIV-infected persons","volume":"28","author":"Matteelli","year":"2001","journal-title":"Sex Transm Dis"},{"key":"key20160405092302285_ref1-bib121","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1086\/322593","article-title":"Phase II double-blind, placebo-controlled study of the safety and efficacy of cidofovir topical gel for the treatment of patients with human papillomavirus infection","volume":"33","author":"Snoeck","year":"2001","journal-title":"Clin Infect Dis"},{"key":"key20160405092302285_ref1-bib122","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1159\/000246818","article-title":"Topical 0.3% and 0.5% podophyllotoxin cream for self-treatment of condylomata acuminata in women. A placebo-controlled, double-blind study","volume":"189","author":"Syed","year":"1994","journal-title":"Dermatology"},{"key":"key20160405092302285_ref1-bib123","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1159\/000246530","article-title":"Human leukocyte interferon-alpha versus podophyllotoxin in cream for the treatment of genital warts in males. A placebo-controlled, double-blind, comparative study","volume":"191","author":"Syed","year":"1995","journal-title":"Dermatology"},{"key":"key20160405092302285_ref1-bib124","first-page":"255","article-title":"Management of genital warts in women with human leukocyte interferon-alpha vs. podophyllotoxin in cream: a placebo-controlled, double-blind, comparative study","volume":"73","author":"Syed","year":"1995","journal-title":"J Mol Med (Berl)"},{"key":"key20160405092302285_ref1-bib125","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1086\/517472","article-title":"A randomized, controlled, molecular study of condylomata acuminata clearance during treatment with imiquimod","volume":"178","author":"Tyring","year":"1998","journal-title":"J Infect Dis"},{"key":"key20160405092302285_ref1-bib126","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1097\/00007435-199205000-00012","article-title":"Self-treatment using a 0.5% podophyllotoxin cream of external genital condylomata acuminata in women. A placebo-controlled, double-blind study","volume":"19","author":"von Krogh","year":"1992","journal-title":"Sex Transm Dis"},{"key":"key20160405092302285_ref1-bib127","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1136\/sti.70.2.105","article-title":"Self-treatment using 0.25%\u20130.50% podophyllotoxin-ethanol solutions against penile condylomata acuminata: a placebo-controlled comparative study","volume":"70","author":"von Krogh","year":"1994","journal-title":"Genitourin Med"},{"key":"key20160405092302285_ref1-bib128","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1097\/00002030-200202150-00017","article-title":"Combined surgery and cidofovir is an effective treatment for genital warts in HIV-infected patients","volume":"16","author":"Orlando","year":"2002","journal-title":"AIDS"},{"key":"key20160405092302285_ref1-bib129","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1097\/00007435-200104000-00007","article-title":"Treatment of external genital warts in men using 5% imiquimod cream applied three times a week, once daily, twice daily, or three times a day","volume":"28","author":"Fife","year":"2001","journal-title":"Sex Transm Dis"},{"key":"key20160405092302285_ref1-bib130","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1258\/095646206777689161","article-title":"An open-label phase II pilot study investigating the optimal duration of imiquimod 5% cream for the treatment of external genital warts in women","volume":"17","author":"Garland","year":"2006","journal-title":"Int J STD AIDS"},{"key":"key20160405092302285_ref1-bib131","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1097\/OLQ.0b013e3181f68ebb","article-title":"Efficacy and safety of imiquimod versus podophyllotoxin in the treatment of anogenital warts","volume":"38","author":"Komericki","year":"2011","journal-title":"Sex Transm Dis"},{"key":"key20160405092302285_ref1-bib132","first-page":"67","article-title":"A comparative study of efficacy of imiquimod 5% versus podophyllin 20% in treatment of external and genital warts (60 patients)","volume":"27","author":"Padhiar","year":"2006","journal-title":"Indian J Sex Transm Dis"},{"key":"key20160405092302285_ref1-bib133","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1258\/ijsa.2007.007196","article-title":"Comparison of cryotherapy to imiquimod 5% in the treatment of anogenital warts","volume":"19","author":"Stefanaki","year":"2008","journal-title":"Int J STD AIDS"},{"key":"key20160405092302285_ref1-bib134","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/S0020-7292(01)00573-2","article-title":"Increased frequency of dosing of imiquimod 5% cream in the treatment of external genital warts in women","volume":"76","author":"Trofatter","year":"2002","journal-title":"Int J Gynaecol Obstet"},{"key":"key20160405092302285_ref1-bib135","first-page":"361","article-title":"An open-label comparative study to evaluate the efficacy and tolerability of imiquimod 5% cream alone and combined with cryotherapy in the treatment of recalcitrant anogenital warts","volume":"19","author":"Tuncel","year":"2005","journal-title":"Eur Acad Dermatol Venereol"},{"key":"key20160405092302285_ref1-bib136","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1136\/sti.64.4.263","article-title":"Podophyllotoxin 0.5% v podophyllin 20% to treat penile warts","volume":"64","author":"Edwards","year":"1988","journal-title":"Genitourin Med"},{"key":"key20160405092302285_ref1-bib137","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1177\/095646249500600407","article-title":"Self-treatment of female external genital warts with 0.5% podophyllotoxin cream (Condyline) vs. weekly applications of 20% podophyllin solution","volume":"6","author":"Hellberg","year":"1995","journal-title":"Int J STD AIDS"},{"key":"key20160405092302285_ref1-bib138","first-page":"146","article-title":"Topical podophyllin and podophyllotoxin for treatment of genital warts: a comparative study","volume":"48","author":"Kar","year":"2003","journal-title":"Indian J Dermatol"},{"key":"key20160405092302285_ref1-bib139","first-page":"1223","article-title":"Zur behandlung von condylomata acuminata mit podophyllotoxin","volume":"11","author":"Landthaler","year":"1987","journal-title":"Dt Dermatol"},{"key":"key20160405092302285_ref1-bib140","first-page":"31","article-title":"Podophyllotoxin for treatment of genital warts in males. A comparison with conventional podophyllin therapy","volume":"2","author":"Lassus","year":"1984","journal-title":"Eur J Sex Transm Dis"},{"key":"key20160405092302285_ref1-bib141","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1136\/sti.71.6.391","article-title":"A single-blind study of podophyllotoxin cream 0.5% and podophyllotoxin solution 0.5% in male patients with genital warts","volume":"71","author":"Petersen","year":"1995","journal-title":"Genitourin Med"},{"key":"key20160405092302285_ref1-bib142","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1136\/sti.71.6.387","article-title":"Topical treatment of genital warts in men, an open study of podophyllotoxin cream compared with solution","volume":"71","author":"Strand","year":"1995","journal-title":"Genitourin Med"},{"key":"key20160405092302285_ref1-bib143","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1159\/000247193","article-title":"Topical treatment of penile condylomata acuminata with podophyllotoxin 0.3% solution, 0.3% cream and 0.15% cream. A comparative open study","volume":"187","author":"Syed","year":"1993","journal-title":"Dermatology"},{"key":"key20160405092302285_ref1-bib144","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1136\/sti.73.3.184","article-title":"Podophyllin 0.5% or 2.0% v podophyllotoxin 0.5% for the self treatment of penile warts: a double blind randomised study","volume":"73","author":"White","year":"1997","journal-title":"Genitourin Med"},{"key":"key20160405092302285_ref1-bib145","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1136\/sti.59.2.124","article-title":"Treatment of anogenital warts. Comparison of trichloracetic acid and podophyllin versus podophyllin alone","volume":"59","author":"Gabriel","year":"1983","journal-title":"Br J Vener Dis"},{"key":"key20160405092302285_ref1-bib146","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1016\/S0140-6736(85)92677-7","article-title":"Comparison of podophyllin application with simple surgical excision in clearance and recurrence of perianal condylomata acuminata","volume":"2","author":"Jensen","year":"1985","journal-title":"Lancet"},{"key":"key20160405092302285_ref1-bib147","first-page":"37","article-title":"Self-treatment of condylomata acuminata with podophyllin resin","volume":"229","author":"Maiti","year":"1985","journal-title":"Practitioner"},{"key":"key20160405092302285_ref1-bib148","first-page":"22","article-title":"Comparison of podophyllin and trichloroacetic acid for the treatment of genital warts","volume":"56","author":"Nath","year":"1990","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"key20160405092302285_ref1-bib149","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1258\/095646207781024711","article-title":"Comparison of the effectiveness of commonly used clinic-based treatments for external genital warts","volume":"18","author":"Sherrard","year":"2007","journal-title":"Int J STD AIDS"},{"key":"key20160405092302285_ref1-bib150","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1136\/sti.57.3.208","article-title":"Podophyllin 10% and 25% in the treatment of ano-genital warts. A comparative double-blind study","volume":"57","author":"Simmons","year":"1981","journal-title":"Br J Vener Dis"},{"key":"key20160405092302285_ref1-bib151","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1136\/sti.66.1.16","article-title":"Treatment of external genital warts: a randomised clinical trial comparing podophyllin, cryotherapy, and electrodesiccation","volume":"66","author":"Stone","year":"1990","journal-title":"Genitourin Med"},{"key":"key20160405092302285_ref1-bib152","first-page":"16","article-title":"The efficacy of podophylin 20% and thricholoroacetic acid 30% in the treatment of genital wart","volume":"1","author":"Tabari","year":"2010","journal-title":"Casp J Intern Med"},{"key":"key20160405092302285_ref1-bib153","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1097\/00007435-199320060-00008","article-title":"Treatment of external genital warts comparing cryotherapy (liquid nitrogen) and trichloroacetic acid","volume":"20","author":"Abdullah","year":"1993","journal-title":"Sex Transm Dis"},{"key":"key20160405092302285_ref1-bib154","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1136\/sti.63.6.390","article-title":"Cryotherapy compared with trichloroacetic acid in treating genital warts","volume":"63","author":"Godley","year":"1987","journal-title":"Genitourin Med"},{"key":"key20160405092302285_ref1-bib155","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1007\/s10350-007-9041-2","article-title":"Earlier eradication of intra-anal warts with argon plasma coagulator combined with imiquimod cream compared with argon plasma coagulator alone: a prospective, randomized trial","volume":"50","author":"Viazis","year":"2007","journal-title":"Dis Colon Rectum"},{"key":"key20160405092302285_ref1-bib156","first-page":"187","article-title":"CO2 laser therapy versus cryotherapy in treatment of genital warts; a randomized controlled trial (RCT)","volume":"4","author":"Azizjalali","year":"2012","journal-title":"Iran J Microbiol"},{"key":"key20160405092302285_ref1-bib157","first-page":"455","article-title":"High- and low-power CO2 lasers. Comparison of results for three clinical indications","volume":"38","author":"Bar-Am","year":"1993","journal-title":"J Reprod Med"},{"key":"key20160405092302285_ref1-bib158","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1089\/gyn.1995.11.41","article-title":"Treating vaginal and external anogenital condylomas with electrosurgery vs. CO2 laser ablation","volume":"11","author":"Ferenczy","year":"1995","journal-title":"J Gynecol Surg"},{"key":"key20160405092302285_ref1-bib159","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1136\/sti.2009.038075","article-title":"A multicentre, randomised, double-blind, placebo controlled study of cryotherapy versus cryotherapy and podophyllotoxin cream as treatment for external anogenital warts","volume":"85","author":"Gilson","year":"2009","journal-title":"Sex Transm Infect"},{"key":"key20160405092302285_ref1-bib160","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1136\/sti.57.4.273","article-title":"Cryotherapy versus electrocautery in the treatment of genital warts","volume":"57","author":"Simmons","year":"1981","journal-title":"Br J Vener Dis"},{"key":"key20160405092302285_ref1-bib161","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1111\/j.1346-8138.1998.tb02429.x","article-title":"Management of female genital warts with an analog of imiquimod 2% in cream: a randomized, double-blind, placebo-controlled study","volume":"25","author":"Syed","year":"1998","journal-title":"J Dermatol"},{"key":"key20160405092302285_ref1-bib162","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1053\/jinf.2000.0709","article-title":"Treatment of external genital warts in men with imiquimod 2% in cream. A placebo-controlled, double-blind study","volume":"41","author":"Syed","year":"2000","journal-title":"J Infect"},{"key":"key20160405092302285_ref1-bib163","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3111\/13696990903451461","article-title":"A cost-effectiveness analysis of sinecatechins in the treatment of external genital warts","volume":"13","author":"Langley","year":"2010","journal-title":"J Med Econ"},{"key":"key20160405092302285_ref1-bib164","doi-asserted-by":"publisher","first-page":"A426","DOI":"10.1016\/S1098-3015(10)75104-4","article-title":"Cost-effectiveness analysis of imiquimod versus podophyllotoxin in treatment of genital\/perianal warts in Poland","volume":"12","author":"Walczak","year":"2009","journal-title":"Value Health"},{"key":"key20160405092302285_ref1-bib165","first-page":"731","article-title":"A model-based comparison of cost effectiveness of imiquimod versus podophyllotoxin for the treatment of external anogenital warts in France","volume":"130","author":"Lafuma","year":"2003","journal-title":"Ann Dermatol Venereol"},{"key":"key20160405092302285_ref1-bib166","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1258\/095646203321264827","article-title":"The cost-effectiveness of patient-applied treatments for anogenital warts","volume":"14","author":"Williams","year":"2003","journal-title":"Int J STD AIDS"},{"key":"key20160405092302285_ref1-bib167","first-page":"337","article-title":"Direct medical costs for surgical and medical treatment of condylomata acuminata","volume":"137","author":"Alam","year":"2001","journal-title":"Arch Dermatol"},{"key":"key20160405092302285_ref1-bib168","first-page":"3S27","article-title":"Medicoeconomic analysis of the treatment of external condyloma acuminatum","volume":"127","author":"Fagnani","year":"2000","journal-title":"Ann Dermatol Venereol"},{"key":"key20160405092302285_ref1-bib169","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1016\/S0149-2918(00)87244-6","article-title":"Modeling the impact of treatment options in genital warts: patient-applied versus physician-administered therapies","volume":"21","author":"Langley","year":"1999","journal-title":"Clin Ther"},{"key":"key20160405092302285_ref1-bib170","first-page":"69","article-title":"The cost effectiveness of patient-applied versus provider-administered intervention strategies for the treatment of external genital warts","volume":"5","author":"Langley","year":"1999","journal-title":"Am J Manag Care"},{"key":"key20160405092302285_ref1-bib171","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1177\/095646249400500405","article-title":"The cost effectiveness of treatment of genital warts with podophyllotoxin","volume":"5","author":"Mohanty","year":"1994","journal-title":"Int J STD AIDS"},{"key":"key20160405092302285_ref1-bib172","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1185\/030079906X99972","article-title":"Costs of detection and treatment of cervical cancer, cervical dysplasia and genital warts in the UK","volume":"22","author":"Brown","year":"2006","journal-title":"Curr Med Res Opin"},{"key":"key20160405092302285_ref1-bib173","doi-asserted-by":"publisher","first-page":"A271","DOI":"10.1016\/j.jval.2011.08.222","article-title":"Costs of managing genital warts in the UK","volume":"14","author":"Carroll","year":"2011","journal-title":"Value Health"},{"key":"key20160405092302285_ref1-bib174","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1258\/0956462041558168","article-title":"The costs of treating external genital warts in England and Wales: a treatment pattern analysis","volume":"15","author":"Langley","year":"2004","journal-title":"Int J STD AIDS"},{"key":"key20160405092302285_ref1-bib175","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1097\/OLQ.0b013e3181a74c2c","article-title":"Cost of treatment and QALYs lost due to genital warts: data for the economic evaluation of HPV vaccines in the United Kingdom","volume":"36","author":"Woodhall","year":"2009","journal-title":"Sex Transm Dis"},{"key":"key20160405092302285_ref1-bib176","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1136\/sextrans-2011-050073","article-title":"The impact of genital warts: loss of quality of life and cost of treatment in eight sexual health clinics in the UK","volume":"87","author":"Woodhall","year":"2011","journal-title":"Sex Transm Infect"},{"key":"key20160405092302285_ref1-bib177","doi-asserted-by":"publisher","first-page":"135","DOI":"10.3111\/13696990801961611","article-title":"Economic burden associated with the management of cervical cancer, cervical dysplasia and genital warts in Belgium","volume":"11","author":"Annemans","year":"2008","journal-title":"J Med Econ"},{"key":"key20160405092302285_ref1-bib178","doi-asserted-by":"publisher","first-page":"e49699","DOI":"10.1371\/journal.pone.0049699","article-title":"Economic burden of human papillomavirus-related diseases in Italy","volume":"7","author":"Baio","year":"2012","journal-title":"PLOS ONE"},{"key":"key20160405092302285_ref1-bib179","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1093\/eurpub\/ckn127","article-title":"Epidemiology and cost of treatment of genital warts in Spain","volume":"19","author":"Castellsagu\u00e9","year":"2009","journal-title":"Eur J Public Health"},{"key":"key20160405092302285_ref1-bib180","doi-asserted-by":"publisher","first-page":"6016","DOI":"10.1016\/j.vaccine.2012.07.056","article-title":"Estimates of the annual direct medical costs of the prevention and treatment of disease associated with human papillomavirus in the United States","volume":"30","author":"Chesson","year":"2012","journal-title":"Vaccine"},{"key":"key20160405092302285_ref1-bib181","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1136\/sti.2008.033837","article-title":"Determining the cost of genital warts: a study from Ireland","volume":"85","author":"Dee","year":"2009","journal-title":"Sex Transm Infect"},{"key":"key20160405092302285_ref1-bib182","doi-asserted-by":"publisher","first-page":"A548","DOI":"10.1016\/S1098-3015(11)73293-4","article-title":"PIN13 Burden and medical costs of anogenital warts in Bangkok, Thailand","volume":"7","author":"Dhitavat","year":"2010","journal-title":"Value Health"},{"key":"key20160405092302285_ref1-bib183","doi-asserted-by":"publisher","first-page":"365","DOI":"10.2165\/00128071-200506060-00004","article-title":"Human papillomavirus: burden of illness and treatment cost considerations","volume":"6","author":"Fox","year":"2005","journal-title":"Am J Clin Dermatol"},{"key":"key20160405092302285_ref1-bib184","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3109\/00365548.2010.541492","article-title":"The annual costs associated with human papillomavirus types 6, 11, 16, and 18 infections in Finland","volume":"43","author":"Herse","year":"2011","journal-title":"Scand J Infect Dis"},{"key":"key20160405092302285_ref1-bib185","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/1471-2334-8-76","article-title":"Estimation of the incidence of genital warts and the cost of illness in Germany: a cross-sectional study","volume":"8","author":"Hillemanns","year":"2008","journal-title":"BMC Infect Dis"},{"key":"key20160405092302285_ref1-bib186","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1185\/03007990903136378","article-title":"Assessing incidence and economic burden of genital warts with data from a US commercially insured population","volume":"25","author":"Hoy","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"key20160405092302285_ref1-bib187","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.ajog.2008.03.064","article-title":"The economic burden of noncervical human papillomavirus disease in the United States","volume":"198","author":"Hu","year":"2008","journal-title":"Am J Obstet Gynecol"},{"key":"key20160405092302285_ref1-bib188","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1086\/375074","article-title":"The health and economic burden of genital warts in a set of private health plans in the United States","volume":"36","author":"Insinga","year":"2003","journal-title":"Clin Infect Dis"},{"key":"key20160405092302285_ref1-bib189","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.2165\/00019053-200523110-00004","article-title":"Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: analytic framework and review of the literature","volume":"23","author":"Insinga","year":"2005","journal-title":"Pharmacoeconomics"},{"key":"key20160405092302285_ref1-bib190","doi-asserted-by":"publisher","first-page":"305","DOI":"10.7314\/APJCP.2012.13.1.305","article-title":"Health and economic burden of HPV-related diseases in Singapore","volume":"13","author":"Low","year":"2012","journal-title":"Asian Pac J Cancer Prev"},{"key":"key20160405092302285_ref1-bib191","doi-asserted-by":"publisher","first-page":"A441","DOI":"10.1016\/j.jval.2011.08.1144","article-title":"Cost of HPV associated diseases in Saint-Petersburg","author":"Lyalina","year":"2011","journal-title":"Value Health"},{"key":"key20160405092302285_ref1-bib192","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1136\/sti.2008.030999","article-title":"Epidemiology and costs associated with genital warts in Canada","volume":"85","author":"Marra","year":"2009","journal-title":"Sex Transm Infect"},{"key":"key20160405092302285_ref1-bib193","doi-asserted-by":"publisher","first-page":"3175","DOI":"10.1185\/03007990802485694","article-title":"Treatment patterns and associated costs for genital warts in Italy","volume":"24","author":"Merito","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"key20160405092302285_ref1-bib194","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.gyobfe.2006.12.010","article-title":"Anogenital warts incidence, medical management and costs in women consulting gynaecologists in France","volume":"35","author":"Monson\u00e9go","year":"2007","journal-title":"Gynecol Obstet Fertil"},{"key":"key20160405092302285_ref1-bib195","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1097\/OLQ.0b013e318285c6d2","article-title":"The estimated direct medical cost of selected sexually transmitted infections in the United States, 2008","volume":"40","author":"Owusu-Edusei","year":"2013","journal-title":"Sex Transm Dis"},{"key":"key20160405092302285_ref1-bib196","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1136\/sti.2009.040188","article-title":"Genital warts incidence and healthcare resource utilisation in Australia","volume":"86","author":"Pirotta","year":"2010","journal-title":"Sex Transm Infect"},{"key":"key20160405092302285_ref1-bib197","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1002\/ijc.28145","article-title":"The burden and costs of prevention and management of genital disease caused by HPV in women: a population-based registry study in Finland","volume":"133","author":"Salo","year":"2013","journal-title":"Int J Cancer"},{"key":"key20160405092302285_ref1-bib198","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1111\/j.1365-4362.1996.tb03635.x","article-title":"The cost of treating genital warts","volume":"35","author":"Strauss","year":"1996","journal-title":"Int J Dermatol"},{"key":"key20160405092302285_ref1-bib199","doi-asserted-by":"publisher","first-page":"A511","DOI":"10.1016\/S1098-3015(11)73103-5","article-title":"PCN10 Estimation of the health and cost burden of HPV-related diseases in Thailand","volume":"13","author":"Termrungruanglert","year":"2010","journal-title":"Value Health"},{"key":"key20160405092302285_ref1-bib200","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/S0149-2918(02)85014-7","article-title":"A retrospective analysis of costs and patterns of treatment for external genital warts in the Netherlands","volume":"24","author":"van der Meijden","year":"2002","journal-title":"Clin Ther"},{"key":"key20160405092302285_ref1-bib201","volume-title":"Cryotherapy to Anogenital Warts","author":"Augustovski","year":"2009"},{"key":"key20160405092302285_ref1-bib202","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1258\/09564620260216371","article-title":"Cost-effectiveness of imiquimod for anogenital warts","volume":"13","author":"Birley","year":"2002","journal-title":"Int J STD AIDS"},{"key":"key20160405092302285_ref1-bib203","first-page":"649","article-title":"Comparing therapy costs for physician treatment of warts","volume":"2","author":"Clemons","year":"2003","journal-title":"J Drugs Dermatol"},{"key":"key20160405092302285_ref1-bib204","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1097\/OLQ.0b013e31816c5cda","article-title":"National burden of genital warts: a first step in defining the problem","volume":"35","author":"Dempsey","year":"2008","journal-title":"Sex Transm Dis"},{"key":"key20160405092302285_ref1-bib205","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1007\/s11538-008-9338-x","article-title":"A multi-type HPV transmission model","volume":"70","author":"Elbasha","year":"2008","journal-title":"Bull Math Biol"},{"key":"key20160405092302285_ref1-bib206","doi-asserted-by":"publisher","first-page":"2880","DOI":"10.1002\/sim.4062","article-title":"A modeling framework for the analysis of HPV incidence and persistence: a semi-parametric approach for clustered binary longitudinal data analysis","volume":"29","author":"Kong","year":"2010","journal-title":"Stat Med"},{"key":"key20160405092302285_ref1-bib207","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1097\/01.olq.0000145851.76025.ad","article-title":"Rate and predictors of new genital warts claims and genital warts-related healthcare utilization among privately insured patients in the United States","volume":"31","author":"Koshiol","year":"2004","journal-title":"Sex Transm Dis"},{"key":"key20160405092302285_ref1-bib208","first-page":"533","article-title":"Direct medical cost for surgical and medical treatment of condylomata acuminata","volume":"138","author":"Kuwahara","year":"2002","journal-title":"Arch Dermatol"},{"key":"key20160405092302285_ref1-bib209","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1258\/0956462041211199","article-title":"Patterns of treatment and resource utilization in the treatment of external genital warts in England and Wales","volume":"15","author":"Langley","year":"2004","journal-title":"Int J STD AIDS"},{"key":"key20160405092302285_ref1-bib210","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1177\/095646249500600320","article-title":"The cost effectiveness of hospital-based 25% podophyllin vs home-based 0.5% podophyllotoxin in the treatment of anogenital warts","volume":"6","author":"Lewis","year":"1995","journal-title":"Int J STD AIDS"},{"key":"key20160405092302285_ref1-bib211","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/11591170-000000000-00000","article-title":"Economic and humanistic burden of external genital warts","volume":"30","author":"Raymakers","year":"2012","journal-title":"Pharmacoeconomics"},{"key":"key20160405092302285_ref1-bib212","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.puhe.2011.01.016","article-title":"Appraisal of the burden of genital warts from a healthcare and individual patient perspective","volume":"125","author":"Scarbrough Lefebvre","year":"2011","journal-title":"Public Health"},{"key":"key20160405092302285_ref1-bib213","first-page":"391","article-title":"Model for predicting the burden and cost of treatment in cervical cancer and HPV-related diseases in Thailand","volume":"33","author":"Termrungruanglert","year":"2012","journal-title":"Eur J Gynaecol Oncol"},{"key":"key20160405092302285_ref1-bib214","doi-asserted-by":"publisher","first-page":"A445","DOI":"10.1016\/j.jval.2011.08.1163","article-title":"Costs and consequences of HPV vaccination in Thailand: results of a prevalence based model","author":"Van Enckevort","year":"2011","journal-title":"Value Health"},{"key":"key20160405092302285_ref1-bib215","doi-asserted-by":"publisher","first-page":"A350","DOI":"10.1016\/j.jval.2013.08.163","article-title":"The costs of managing genital warts in the UK by devolved nation: England, Scotland, Wales and Northern Ireland","volume":"16","author":"Chapman","year":"2013","journal-title":"Value Health"},{"issue":"36","key":"key20160405092302285_ref1-bib216","doi-asserted-by":"publisher","DOI":"10.3310\/hta8360","article-title":"Review of guidelines for good practice in decision-analytic modelling in health technology assessment","volume":"8","author":"Philips","year":"2004","journal-title":"Health Technol Assess"},{"key":"key20160405092302285_ref1-bib217","volume-title":"Unit Costs of Health and Social Care 2013","author":"Curtis","year":"2013"},{"key":"key20160405092302285_ref1-bib218","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/S0002-9343(97)00181-2","article-title":"Therapeutic approaches to genital warts","volume":"102","author":"Beutner","year":"1997","journal-title":"Am J Med"},{"key":"key20160405092302285_ref1-bib219","first-page":"1137","article-title":"Noncervical human papillomavirus genital infections","volume":"52","author":"Mayeaux","year":"1995","journal-title":"Am Fam Physician"},{"key":"key20160405092302285_ref1-bib220","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/S0733-8635(05)70441-1","article-title":"Therapeutic approaches to papillomavirus infections","volume":"15","author":"Baker","year":"1997","journal-title":"Dermatol Clin"},{"key":"key20160405092302285_ref1-bib221","volume-title":"NICE Guide to the Methods of Technology Appraisal 2013","author":"National Institute for Health and Care Excellence","year":"2013"},{"key":"key20160405092302285_ref1-bib222","doi-asserted-by":"publisher","first-page":"A38","DOI":"10.1016\/j.jval.2013.03.219","article-title":"Loss of health utilities due to HPV-induced diseases in men and women: a multicenter Italian study","volume":"16","author":"Mennini","year":"2013","journal-title":"Value Health"},{"key":"key20160405092302285_ref1-bib223","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/1471-2458-12-153","article-title":"Impact of genital warts on health related quality of life in men and women in mainland China: a multicenter hospital-based cross-sectional study","volume":"12","author":"Shi","year":"2012","journal-title":"BMC Public Health"},{"key":"key20160405092302285_ref1-bib224","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1016\/j.clinthera.2011.06.012","article-title":"Time trade-off procedure for measuring health utilities loss with human papillomavirus-induced diseases: a multicenter, retrospective, observational pilot study in Italy","volume":"33","author":"Mennini","year":"2011","journal-title":"Clin Ther"},{"key":"key20160405092302285_ref1-bib225","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1136\/sti.2009.039982","article-title":"Loss of quality of life associated with genital warts: baseline analyses from a prospective study","volume":"87","author":"Senecal","year":"2011","journal-title":"Sex Transm Infect"},{"key":"key20160405092302285_ref1-bib226","doi-asserted-by":"publisher","first-page":"5399","DOI":"10.1016\/j.vaccine.2007.04.086","article-title":"The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada","volume":"25","author":"Brisson","year":"2007","journal-title":"Vaccine"},{"key":"key20160405092302285_ref1-bib227","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1097\/OLQ.0b013e3182215512","article-title":"The impact of anogenital warts on health-related quality of life: a 6-month prospective study","volume":"38","author":"Drolet","year":"2011","journal-title":"Sex Transm Dis"},{"key":"key20160405092302285_ref1-bib228","doi-asserted-by":"publisher","first-page":"A403","DOI":"10.1016\/S1098-3015(11)72661-4","article-title":"The experience of external genital warts and genital herpes on quality of life","volume":"13","author":"Langley","year":"2010","journal-title":"Value Health"},{"key":"key20160405092302285_ref1-bib229","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1097\/OLQ.0b013e318191a55e","article-title":"Patients with genital warts have a decreased quality of life","volume":"36","author":"Marra","year":"2009","journal-title":"Sex Transm Dis"},{"key":"key20160405092302285_ref1-bib230","unstructured":"Fiander A, Cohet C. Psychosocial Impact of HPV-related Diseases in Women in the UK: The PasQual Study. Eurogin Conference, Monte Carlo, Monaco, 17\u201320 February 2010. URL: www.eurogin.com\/2010\/EUROGIN2010_Abstracts.pdf (accessed 27 November 2015)."},{"key":"key20160405092302285_ref1-bib231","unstructured":"Fiander A, Cohet C. Psychosocial Impact of HPV-related Diseases in Men in the UK: The PasQual Study. Eurogin Conference, Monte Carlo, Monaco, 17\u201320 February 2010. URL: www.eurogin.com\/2010\/EUROGIN2010_Abstracts.pdf (accessed 27 November 2015)."},{"key":"key20160405092302285_ref1-bib232","unstructured":"Mennini, FS, Panatto D, Marcellusi A, Cristoforoni P, De Vincenzo R, Di Capua E, et al. The time-trade off approach to measure patients\u2019 preferences for health states associated with HPV-related pathologies: a multicenter study performed in Italy. Health Technology Assessment International (HTAi) Society, 7th Annual Meeting. Dublin, Ireland, 6\u20139 June 2010. Abstract M5\u201353, p. 192."},{"key":"key20160405092302285_ref1-bib233","unstructured":"Myers E, Green S, Lipkus I. Patient Preferences for Health States Related to HPV Infection: Visual Analog Scale Versus Time Trade-off Elicitation. 21st International Papillomavirus Conference, Mexico, February 2004. Abstract 524."},{"key":"key20160405092302285_ref1-bib234","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1586\/14737167.2014.881253","article-title":"Universal vaccination with the quadrivalent HPV vaccine in Austria: impact on virus circulation, public health and cost-effectiveness analysis","volume":"14","author":"Bresse","year":"2014","journal-title":"Expert Rev"},{"key":"key20160405092302285_ref1-bib235","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1002\/ijc.28541","article-title":"Potential cost-effectiveness of the nonavalent human papillomavirus (HPV) vaccine","volume":"134","author":"Drolet","year":"2014","journal-title":"Int J Cancer"},{"key":"key20160405092302285_ref1-bib236","first-page":"225","article-title":"Cost-effectiveness evaluation of quadrivalent human papilloma virus vaccine for HPV-related disease in Iran","volume":"13","author":"Khatibi","year":"2014","journal-title":"Iran J Pharm Res"},{"key":"key20160405092302285_ref1-bib237","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1186\/1471-2458-13-1065","article-title":"Impact of human papillomavirus-related genital diseases on quality of life and psychosocial wellbeing: results of an observational, health-related quality of life study in the UK","volume":"13","author":"Dominiak-Felden","year":"2013","journal-title":"BMC Public Health"},{"key":"key20160405092302285_ref1-bib238","volume-title":"NHS Reference Costs 2012 to 2013","author":"Department of Health","year":"2013"},{"key":"key20160405092302285_ref1-bib239","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1093\/oso\/9780198526629.003.0005","volume-title":"Decision Modelling for Health Economic Evaluation","author":"Briggs","year":"2006"},{"key":"key20160405092302285_ref1-bib240","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s40273-013-0031-z","article-title":"The cost effectiveness of pharmacological treatments for generalized anxiety disorder","volume":"31","author":"Mavranezouli","year":"2013","journal-title":"Pharmacoeconomics"},{"key":"key20160405092302285_ref1-bib241","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1111\/j.1524-4733.2010.00784.x","article-title":"Network meta-analysis with competing risk outcomes","volume":"13","author":"Ades","year":"2010","journal-title":"Value Health"},{"key":"key20160405092302285_ref1-bib242","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/j.jval.2012.06.012","article-title":"ISPOR-SMDM Modeling Good Research Practices Task Force. Modeling good research practices \u2013 overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1","volume":"15","author":"Caro","year":"2012","journal-title":"Value Health"},{"key":"key20160405092302285_ref1-bib243","volume-title":"Human Papillomavirus Infection: A Randomised Controlled Trial of Imiquimod Cream (5%) Versus Podophyllotoxin Cream (0.15%), in Combination with Quadrivalent Human Papillomavirus or Control Vaccination in the Treatment and Prevention of Recurrence of Anogenital Warts (HIPvac Trial)","author":"International Standard Randomised Controlled Trial Number","year":"2014"},{"key":"key20160405092302285_ref1-bib244","doi-asserted-by":"publisher","first-page":"806105","DOI":"10.1155\/2011\/806105","article-title":"Imiquimod 3.75% cream applied daily to treat anogenital warts: combined results from women in two randomized, placebo-controlled studies","volume":"2011","author":"Baker","year":"2011","journal-title":"Infect Dis Obstet Gynecol"},{"key":"key20160405092302285_ref1-bib245","volume-title":"Safety and Effectiveness Study of Imiquimod Creams in the Treatment of External Genital Warts","author":"ClinicalTrials.gov","year":"2011"},{"key":"key20160405092302285_ref1-bib246","volume-title":"Phase 3 Study of Imiquimod Creams in the Treatment of External Genital Warts","author":"ClinicalTrials.gov","year":"2011"},{"key":"key20160405092302285_ref1-bib247","volume-title":"Statistical Methods in Medical Research","author":"Armitage","year":"1971","edition":"1st edn."},{"key":"key20160405092302285_ref1-bib248","doi-asserted-by":"publisher","first-page":"S76","DOI":"10.1080\/01443619866606","article-title":"Immune response modifiers: imiquimod","volume":"18","author":"Ferenczy","year":"1998","journal-title":"J Obstet Gynaecol"},{"key":"key20160405092302285_ref1-bib249","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S0166-3542(99)00033-9","article-title":"Enhancement of the innate and cellular immune response in patients with genital warts treated with topical imiquimod cream 5%","volume":"43","author":"Arany","year":"1999","journal-title":"Antivir Res"}],"container-title":["Health Technology Assessment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/publications\/hta20240\/hta20240.xml","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2002401","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/publications\/hta20240\/hta20240.xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2003405","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T14:13:51Z","timestamp":1718460831000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/hta\/hta20240\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":249,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2016,3]]}},"alternative-id":["10.3310\/hta20240"],"URL":"https:\/\/doi.org\/10.3310\/hta20240","relation":{},"ISSN":["1366-5278","2046-4924"],"issn-type":[{"value":"1366-5278","type":"print"},{"value":"2046-4924","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"This content has been made freely available to all.","name":"free","label":"Free to read"}]}}